Can mRNA vaccine technology be applied to other diseases beyond COVID-19?

Beyond COVID: Where mRNA is already working in clinical trials

The mRNA platform isn't a one-trick pony. The same lipid nanoparticle technology that delivered COVID-19 vaccines is now being tested against a range of other infectious diseases and cancers. A pivotal phase 3 trial of an mRNA vaccine for respiratory syncytial virus (RSV) in older adults found that a 10-fold increase in neutralizing antibody levels after vaccination was associated with a 56% lower risk of developing RSV lower respiratory tract disease (hazard ratio 0.44) [2]. This shows the immune response triggered by mRNA works similarly for other viruses.

Clinical trials are also underway for mRNA vaccines against influenza, Zika, rabies, and even parasitic diseases like toxoplasmosis and leishmaniasis [6][8]. In cancer, mRNA vaccines are being designed to train the immune system to recognize tumor-specific antigens, with early trials showing the ability to trigger both antibody and T-cell responses against cancer cells [6][10]. A systematic analysis of all mRNA vaccine trials registered up to July 2025 found that indications have 'rapidly expanded from infectious diseases to multiple fields such as tumors, autoimmune diseases, and metabolic diseases' [4].

How it works and what makes it so versatile

The key advantage of mRNA technology is its flexibility. Instead of growing a virus or purifying a protein, you simply design a genetic sequence that codes for the antigen you want the body to produce. This means the same manufacturing process can be adapted to a new target in weeks [5]. The mRNA is wrapped in a lipid nanoparticle (LNP) to protect it and get it into cells [7].

This platform can also be tweaked to boost immune responses. For example, researchers have added a molecule called Pam2Cys (which activates Toll-like receptor 2/6) to mRNA-LNP vaccines, and in mouse models this significantly improved both antibody and T-cell responses against tumors and a surrogate COVID-19 virus [9]. The ability to 'mix and match' the mRNA sequence and the delivery system makes the platform adaptable to many diseases.

Challenges still to overcome: stability, delivery, and public trust

Despite the promise, mRNA vaccines face real hurdles. The mRNA molecule is fragile and degrades quickly, so current vaccines require ultra-cold storage [5]. Delivering mRNA to the right cells in the body (e.g., targeting specific organs for cancer therapy) is still a major technical challenge [7]. For protein replacement therapies or gene editing, the mRNA needs to produce high levels of protein for a longer time, which requires further optimization of the LNP carrier [5][7].

Public acceptance is another barrier. A global survey of over 70,000 people in 70 countries found that only 35% were comfortable with the idea of novel mRNA medicines, with even lower acceptance among women (33%) [3]. Vaccine hesitancy was also a problem during COVID-19 rollout, with 42% of unvaccinated adults in rural California reporting hesitancy [1]. Overcoming this will require transparent communication and continued safety monitoring.

Sources used in this answer

Related research questions